Aktana and Cantab Pi Bring Together 2M+ Data Sets and Predictive Analytics at Scale to Optimize HCP Engagement
16.11.2021 16:13:00 EET | Business Wire | Press release
Aktana, the leader in intelligent customer engagement for the global life sciences industry, announced a new partnership with Cantab Pi, a data science company based in Cambridge, UK. Founded to address the unique data needs of European markets, Cantab Pi brings dynamic targeting capabilities and more than two million healthcare professional (HCP) profiles from a range of sources, including social media and clinical journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005444/en/
Investment in artificial intelligence (AI) and machine learning continues to grow across the commercial life sciences industry, but many companies limit its use to a single region or brand—never maximizing the value of their investments. Cantab Pi’s sophisticated analytical models and social listening tools allow life sciences organizations to sharpen digital targeting and optimize their omnichannel marketing mix—even in markets where traditional HCP-level data is commercially unavailable. Combined with Aktana’s scalable intelligent engagement platform, the partnership offers life sciences companies deeper insights for orchestrated omnichannel engagement with HCPs across all customer-facing teams, brands, therapeutic areas, and geographies.
Novartis, a leader in digital transformation, will be the first to implement the blended solution. “We have a business imperative to harness as much intelligence as possible from the wealth of data we manage,” said Paul Thompson, global director of AI enablement and orchestration at Novartis. “This new program is part of our continued mission to find innovative ways to segment, engage and follow up with our customers.”
“With the increased use of digital technology, multiple channels, and heightened expectation for consumer-like engagement, the industry needs intelligence engines to personalize and coordinate customer engagement,” said Siniša Slijepčević, founder and CEO at Cantab Pi. “By feeding models with daily insights from the channels where HCPs are engaging most, like Twitter, companies more accurately personalize campaigns and see double or triple digital engagement as a result. With Aktana, we enable life sciences organizations to optimize HCP relationships, increase efficiency, and better support physicians.”
With more than 300 combined deployments, Aktana and Cantab Pi bring proven technologies to the life sciences industry. In addition to Aktana’s Contextual Intelligence platform, new offerings include social media listening tools that aggregate more than 500 data points daily across more than two million HCP social media profiles and dynamic targeting models. For commercial teams, this translates to near real-time insights delivered in their daily workflows on the digital and scientific influence of Key Opinion Leaders (KOLs), HCP affinity for digital engagement, and social media indicators for future sales. The partnership also allows teams to optimize their marketing mix using machine learning and predictive modeling.
“One of the exciting challenges for the industry right now is in identifying the highest-value data sets, building robust predictive models and then having the ability to deploy them on a multi-product/country scale,” said Graham Rapier, vice president, EMEA markets at Aktana. “The Cantab Pi and Aktana partnership provides a powerful solution for this by bringing together comprehensive HCP clinical influence data, advanced marketing mix analytics, and a globally scalable intelligence and orchestration platform.”
About Aktana
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.
About Cantab Pi
Cantab Pi, founded in 2017 in Cambridge, UK, provides innovative Predictive Analytics, Machine Learning and Artificial Intelligence for life sciences, with a focus on marketing and sales. Cantab Pi is already empowering multiple brands on three continents for some of the leading global pharma companies and the most innovative biotechs. Cantab Pi’s vision is to bring together rich external data sources, deep understanding of business needs, state-of-the art analytics, and agile deployment of its Machine Learning as a Service platform, to boost productivity of sales teams and customer engagement. For more information, visit www.cantabpi.com/life-sciences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005444/en/
Contact information
Media Contacts:
Aktana
Lisa Barbadora
610-420-3413
lbarbadora@barbadoraink.com
Cantab Pi
Andrijana Kos Kavran
andrijana.kos.kavran@itfactory.hr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track29.6.2026 13:12:00 EEST | Press release
The Abu Dhabi Autonomous Racing League, A2RL, will make its international racing debut on 5 September 2026 in Imola, Italy, bringing up to 5 fully autonomous racecars based on the Dallara Super Formula SF23 to one of the world’s most iconic and demanding racing circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726789/en/ From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track (Photo: AETOSWire) Organized by ASPIRE, the grand challenges arm of Abu Dhabi’s Advanced Technology Research Council, A2RL has quickly evolved from a bold public testbed for AI under extreme race conditions into a competitive racing series. The upcoming Imola race marks a major step in its global expansion, following two breakthrough seasons at Yas Marina Circuit in Abu Dhabi and opening the championship’s first international chapter before it returns to the UAE capital for the 202
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 13:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career to the world’s most prestigious stages, he has followed a path shaped by conviction and the courage t
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
